Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial ...
MPR14h
Setmelanotide Reduces BMI in Patients With Acquired Hypothalamic Obesity
The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.
Healio17h
Setmelanotide leads to significant decrease in BMI for patients with hypothalamic obesity
A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI ...
Healio4d
Use waist-to-height ratio along with BMI to assess obesity for children
Waist-to-height ratio should be used in conjunction with BMI to assess overweight and obesity in children and adolescents, a ...
Free Malaysia Today1d
Is BMI a misleading tool for measuring obesity?
In women, these variations are more subtle, but a trend emerges: with age, abdominal fat increases (from +1.23% to +4.21%), while muscle mass in the limbs decreases (from -0.81 kg to -2.63 kg).
Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint
Rhythm Pharmaceuticals (RYTM) announced topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 ...